New York, NY (PRWEB) February 09, 2015 -- The ADHD Medication Manufacturing industry has exhibited robust growth, driven by the 42.0% increase in ADHD diagnoses over the past eight years, according to data from Healthline. In addition, according to data from IMS Institute for Healthcare Informatics, the top 20 therapeutic drug classes account for 42.0% of global pharmaceutical spending, which includes ADHD drugs. Moreover, data from IMS Health's National Prescription Audit revealed that the number of ADHD drugs dispensed in the United States has risen at an annualized rate of 6.1% to 80.0 million prescriptions from 2010 to 2013 (latest data available). “Overall, more ADHD drugs were dispensed over that period, due to strong demand from particular demographics, such as male individuals aged 12 to 18, according to Express Script's 2014 Turning Attention to ADHD report,” according to IBISWorld Industry Analyst Sarah Turk.
Due to ADHD being one of the most commonly diagnosed conditions for children in the United States, coupled with the recent recognition of ADHD as a condition that can also afflict adults, these trends have provided a boon to the industry. During the five years to 2015, industry revenue is expected to increase at an annualized rate of 8.0% to $12.9 billion, including a 13.0% uptick in 2015. “In particular, healthcare reform requires healthcare insurance providers to cover mental health services, with the Patient Protection and Affordable Care Act (PPACA) requiring insurers to cover pediatric screenings and vaccinations, including behavioral health assessments,” says Turk. Overall, this trend will enable more children to access behavioral health services, resulting in more patients being able to have their ADHD identified and treated.
In the five years to 2020, industry revenue is forecast to grow. Due to the American Psychiatric Association establishing guidelines for diagnosing ADHD in adults in 2013, this trend will likely bolster utilization rates for ADHD drugs from adults over the next five years. However, some key brand-name ADHD drugs are forecast to lose their patent exclusivity, enabling more generic drugs to inundate the market and thus, intensifying price-based competition.
For more information, visit IBISWorld’s ADHD Medication Manufacturing in the US industry report page.
Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189
IBISWorld industry Report Key Topics
This industry manufactures medications that treat people with attention deficits, such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
Globalization & Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Major Companies
Operating Conditions
Capital Intensity
Key Statistics
Industry Data
Annual Change
Key Ratios
About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.
Gavin Smith, IBISWorld Inc., http://www.ibisworld.com, +1 (310) 866-5042, [email protected]
Share this article